Advertisement

Comparison of continuous 24-h and 14-day monitoring for detection of otherwise unknown atrial fibrillation: a registry to identify Japanese concealed atrial fibrillation (REAL-AF)-based study

  • Koichi NagashimaEmail author
  • Yasuo Okumura
  • Katsuaki Yokoyama
  • Naoya Matsumoto
  • Eizo Tachibana
  • Keiichiro Kuronuma
  • Koji Oiwa
  • Michiaki Matsumoto
  • Toshiaki Kojima
  • Hideyuki Ando
  • Kazumiki Nomoto
  • Ken Arima
  • Atsushi Hirayama
  • the REAL AF StudyInvestigators
Original Article
  • 3 Downloads

Abstract

Early detection of atrial fibrillation (AF) is desirable for preventing strokes. Not only does AF often go undetected in patients being followed up for various disease conditions, but the optimal detection method also remains to be elucidated. In a prospective observational study of 24-h Holter monitoring versus 14-day external loop recording performed for detection of previously undiagnosed AF in 868 Japanese outpatients (aged 75 ± 6 years), with a CHA2DS2-vasc score ≥ 1, but no prior AF episodes, AF was detected during the initial monitoring period in 16 (1.8%) patients, in 7 (1.1% [7/645]) by 24-h monitoring and 9 (4.0% [9/223]) by 14-day monitoring (P = 0.005), and overall in 32 (3.7%) during the 1-year study period. Absence of a beta-blocker therapy and the serum N-terminal pro-brain natriuretic peptide level were independent predictors of a new detection of AF. Oral anticoagulation (OAC) therapy was given to 22 (69%) of the 32 patients in whom AF was detected, and no difference in the incidence of subsequent major adverse events was found between the patients managed with and without oral OAC therapy. Previously unknown AF was documented at a prevalence of 3.7% per year among Japanese with a notable CHA2DS2-VASc score, and 14-day external loop monitoring was significantly more effective for detection of the disorder. A large-scale prospective AF screening study conducted to clarify the type or types of patients who would benefit from “early” OAC therapy for primary stroke prevention is warranted.

Keywords

Atrial fibrillation Continuous monitoring Oral anticoagulant therapy 

Notes

Acknowledgements

We thank Mr. John Martin for his help in the preparation of the manuscript.

Funding

The study was supported by Bristol-Myers Squibb and Pfizer. Okumura Yasuo received the funding described above for this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ (2014) Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129(8):837–847CrossRefGoogle Scholar
  2. 2.
    Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, Aizawa Y, Yamashita T, Atarashi H, Horie M, Ohe T, Doi Y, Shimizu A, Chishaki A, Saikawa T, Yano K, Kitabatake A, Mitamura H, Kodama I, Kamakura S (2009) Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 137(2):102–107CrossRefGoogle Scholar
  3. 3.
    Yamashita T, Ogawa S, Aizawa Y, Atarashi H, Inoue H, Ohe T, Okumura K, Kato T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Nakaya H, Nakayama T, Hirai M, Fukatani M, Mitamura H, Yamazaki T (2003) Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 67(9):738–741CrossRefGoogle Scholar
  4. 4.
    Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itou S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A (2018) Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation- findings from the SAKURA AF registry. Circ J 82(10):2500–2509CrossRefGoogle Scholar
  5. 5.
    Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K (2013) Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF registry. J Cardiol 61(4):260–266CrossRefGoogle Scholar
  6. 6.
    Tomita H, Sasaki S, Hagii J, Metoki N (2018) Covert atrial fibrillation and atrial high-rate episodes as a potential cause of embolic strokes of undetermined source: their detection and possible management strategy. J Cardiol 72(1):1–9CrossRefGoogle Scholar
  7. 7.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18):2370–2375CrossRefGoogle Scholar
  8. 8.
    Mohanty S, Santangeli P, Mohanty P, Di Biase L, Holcomb S, Trivedi C, Bai R, Burkhardt D, Hongo R, Hao S, Beheiry S, Santoro F, Forleo G, Gallinghouse JG, Horton R, Sanchez JE, Bailey S, Hranitzky PM, Zagrodzky J, Natale A (2014) Catheter ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality of life, exercise performance, arrhythmia perception, and arrhythmia-free survival. J Cardiovasc Electrophysiol 25(10):1057–1064CrossRefGoogle Scholar
  9. 9.
    Wu L, Lu Y, Zheng L, Qiao YU, Chen G, Ding L, Hou B, Sun W, Liew R, Zhang S, Yao Y (2016) Comparison of radiofrequency catheter ablation between asymptomatic and symptomatic persistent atrial fibrillation: a propensity score matched analysis. J Cardiovasc Electrophysiol 27(5):531–535CrossRefGoogle Scholar
  10. 10.
    Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V (2015) Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 14(4):377–387CrossRefGoogle Scholar
  11. 11.
    Ramkumar S, Nerlekar N, D’Souza D, Pol DJ, Kalman JM, Marwick TH (2018) Atrial fibrillation detection using single lead portable electrocardiographic monitoring: a systematic review and meta-analysis. BMJ Open 8(9):e024178CrossRefGoogle Scholar
  12. 12.
    Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, Carter C, Baca-Motes K, Felicione E, Sarich T, Topol EJ (2018) Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA 320(2):146–155CrossRefGoogle Scholar
  13. 13.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962CrossRefGoogle Scholar
  14. 14.
    Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, Albert CM, Anderson CS, Antoniou S, Benjamin EJ, Boriani G, Brachmann J, Brandes A, Chao TF, Conen D, Engdahl J, Fauchier L, Fitzmaurice DA, Friberg L, Gersh BJ, Gladstone DJ, Glotzer TV, Gwynne K, Hankey GJ, Harbison J, Hillis GS, Hills MT, Kamel H, Kirchhof P, Kowey PR, Krieger D, Lee VWY, Levin LA, Lip GYH, Lobban T, Lowres N, Mairesse GH, Martinez C, Neubeck L, Orchard J, Piccini JP, Poppe K, Potpara TS, Puererfellner H, Rienstra M, Sandhu RK, Schnabel RB, Siu CW, Steinhubl S, Svendsen JH, Svennberg E, Themistoclakis S, Tieleman RG, Turakhia MP, Tveit A, Uittenbogaart SB, Van Gelder IC, Verma A, Wachter R, Yan BP (2017) Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration. Circulation 135(19):1851–1867CrossRefGoogle Scholar
  15. 15.
    Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, Fought AJ, Topol EJ (2014) Comparison of 24-h Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med 127(1):95e11-17CrossRefGoogle Scholar
  16. 16.
    Zimetbaum PJ, Kim KY, Josephson ME, Goldberger AL, Cohen DJ (1998) Diagnostic yield and optimal duration of continuous-loop event monitoring for the diagnosis of palpitations. A cost-effectiveness analysis. Ann Intern Med 128(11):890–895CrossRefGoogle Scholar
  17. 17.
    Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P (2007) Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 28(4):457–462CrossRefGoogle Scholar
  18. 18.
    Tamura T, Yatabe T, Yokoyama M (2017) Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: a systematic review and meta-analysis. J Clin Anesth 42:1–6CrossRefGoogle Scholar
  19. 19.
    Choi EK, Shen MJ, Lin SF, Chen PS, Oh S (2014) Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs. Europace 16(7):1083–1091CrossRefGoogle Scholar
  20. 20.
    Seegers J, Zabel M, Gruter T, Ammermann A, Weber-Kruger M, Edelmann F, Gelbrich G, Binder L, Herrmann-Lingen C, Groschel K, Hasenfuss G, Feltgen N, Pieske B, Wachter R (2015) Natriuretic peptides for the detection of paroxysmal atrial fibrillation. Open Heart 2(1):e000182CrossRefGoogle Scholar
  21. 21.
    Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA (2009) N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the cardiovascular health study. Circulation 120(18):1768–1774CrossRefGoogle Scholar
  22. 22.
    Wachter R, Lahno R, Haase B, Weber-Kruger M, Seegers J, Edelmann F, Wohlfahrt J, Gelbrich G, Gorlitz A, Kermer P, Vollmann D, Hasenfuss G, Groschel K, Stahrenberg R (2012) Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia–the find-AF study. PLoS ONE 7(4):e34351CrossRefGoogle Scholar
  23. 23.
    Lopez-Lopez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savovic J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R (2017) Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 359:j5058CrossRefGoogle Scholar
  24. 24.
    Kahneman D, Tversky A (1979) Prospect theory - analysis of decision under risk. Econometrica 47(2):263–291CrossRefGoogle Scholar
  25. 25.
    Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA (2003) Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the atrial diagnostics ancillary study of the MOde selection trial (MOST). Circulation 107(12):1614–1619CrossRefGoogle Scholar
  26. 26.
    Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366(2):120–129CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Koichi Nagashima
    • 1
    Email author
  • Yasuo Okumura
    • 1
  • Katsuaki Yokoyama
    • 2
  • Naoya Matsumoto
    • 2
  • Eizo Tachibana
    • 3
  • Keiichiro Kuronuma
    • 3
  • Koji Oiwa
    • 4
  • Michiaki Matsumoto
    • 4
  • Toshiaki Kojima
    • 5
  • Hideyuki Ando
    • 6
  • Kazumiki Nomoto
    • 7
  • Ken Arima
    • 8
  • Atsushi Hirayama
    • 1
  • the REAL AF StudyInvestigators
  1. 1.Division of Cardiology, Department of MedicineNihon University School of MedicineTokyoJapan
  2. 2.Department of CardiologyNihon University HospitalTokyoJapan
  3. 3.Kawaguchi Municipal Medical CenterSaitamaJapan
  4. 4.Yokohama Chuo HospitalYokohamaJapan
  5. 5.Sekishindo HospitalSaitamaJapan
  6. 6.Keiai HospitalTokyoJapan
  7. 7.Tokyo Rinkai HospitalTokyoJapan
  8. 8.Kasukabe Medical CenterSaitamaJapan

Personalised recommendations